LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of BioScrip, Inc. (“BioScrip” or the “Company”) (NASDAQ: BIOS) investors concerning the Company and its officers’ possible violations of federal securities laws. To obtain information or aid in the investigation, please visit the BioScrip investigation page on our website at www.glancylaw.com/case/bioscrip-inc.
On March 8, 2018, BioScrip announced a delay in the filing of its annual report, because the Company had begun an internal accounting review after BioScrip "identified internal control deficiencies in connection with account reconciliations for certain asset and liability accounts." The Company additionally announced that it "has identified and will report a material weakness related to certain spreadsheets used to calculate periodic adjustments to" certain accounts.
On this news, BioScrip's share price fell $0.47, or 15%, to close at $2.60 on March 8, 2018, thereby injuring investors.
If you purchased BioScrip securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley F. Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
